Atara Biotherapeutics, Inc. (ATRA) stock
Close on Nov 11, 2026Market cap $82.61MP/E –Yield –
Atara Biotherapeutics, Inc. saw revenue fall 97.4% to $3.97M over the twelve months to Sep 30, 2026. Operating income fell 151.9% to -$13.62M, moving the operating margin from 17.3% to -343.6%. Free cash flow was -$50.94M. At the latest close the market valued the company at $82.61M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $82.61M
- P/E ratio
- –
- Price to sales
- 20.83
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.97M
- Net income
- -$14.61M
- EPS, diluted
- $2.57
- Free cash flow
- -$50.94M
- Book value per share
- -$2.47
- Diluted shares
- 15M
Trading
- Next earnings
- Mar 15, 2027 (estimated, during market hours)
- Previous close
- $8.10
- Open
- $8.10
- Day's range
- $7.94 – $8.37
- Volume
- 10,340
- Average volume (20 days)
- 21,629
- Beta (5 years)
- 1.65
- 52-week range
- $3.92 – $19.14
- RSI (14 days)
- 44.7
- Volatility (1 year)
- 141.5%
- Relative volume
- 0.22×
- WACC
- 13.1%
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ATRA | S&P 500 | Difference | ATRA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -13.2% | -2.4% | −10.8 pts | ||
| 3 months | -7.9% | -1.2% | −6.8 pts | ||
| Year to date | -54.5% | +12.3% | −66.8 pts | ||
| 1 year | -34.5% | +12.4% | −46.9 pts | ||
| 3 years | +43.3% | +78.8% | −35.6 pts | +12.7% | +21.4% |
| 5 years | -98.1% | +75.2% | −173.3 pts | -54.8% | +11.9% |
| 10 years | -98.4% | +311.1% | −409.5 pts | -33.7% | +15.2% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Atara Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- News
- News
About Atara Biotherapeutics
Biological Products, (No Diagnostic Substances)
Atara Biotherapeutics is a biotechnology company that develops allogeneic T-cell immunotherapies for patients with serious cancers and autoimmune conditions. The company utilizes an Epstein-Barr virus T-cell platform to create off-the-shelf cellular treatments manufactured from donor cells. Its lead product is tabelecleucel, marketed as Ebvallo, an immunotherapy indicated for patients with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease. Atara licenses and commercializes this therapy through a partnership with Pierre Fabre Medicament, serving immunocompromised patients who have undergone solid organ or stem cell transplants and failed conventional treatments.
Company profile, executives and historyAtara Biotherapeutics stock: common questions
What is Atara Biotherapeutics's stock price?
ATRA closed at $8.23 on Nov 11, 2026, up 1.60% on the day. Over the past 52 weeks it traded between $3.92 and $19.14.
What is Atara Biotherapeutics's market cap?
Atara Biotherapeutics was worth $82.61M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
How much revenue does Atara Biotherapeutics make?
Atara Biotherapeutics reported revenue of $3.97M for the twelve months to Sep 30, 2026, down 97.4% from a year earlier.
Does Atara Biotherapeutics pay a dividend?
No. Atara Biotherapeutics has not paid a cash dividend over the last twelve months.
When does Atara Biotherapeutics report earnings next?
Atara Biotherapeutics is expected to report Q4 FY2026 results on Mar 15, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ATRA stock performed over the past year?
Including dividends, ATRA returned -34.5% over the past year, against +12.4% for the S&P 500.
How many ATRA shares are sold short?
0M shares were sold short at the latest FINRA report, 6.63% of the float, or 13.4 days of average trading volume.
Who are Atara Biotherapeutics's competitors?
Companies most similar to Atara Biotherapeutics by business, industry and size include TCRX, FATE, CRBU, EVAX, IPHA.
See a number that looks wrong?